Splenic Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Splenic Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating bortezomib and fludarabine with or without rituximab in relapsed or refractory indolent non-Hodgkin lymphoma or chr…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab with interleukin-12 in several B-cell non-Hodgkin lymphomas. The study status is completed.
-
CLINICAL_TRIALS withdrawal · 2013-06-06Clinical Trial Update: Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating obatoclax mesylate in combination with rituximab and bendamustine hydrochloride for relapsed or refrac…
-
CLINICAL_TRIALS trial_result · 2013-02-01Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]
A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.
-
CLINICAL_TRIALS trial_result · 2011-12-07Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.